Business
Rakovina Therapeutics Announces Share Consolidation Effective Date
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “Consolidation”) will be June 24, 2025. As outlined in the Company’s news release dated May 15, 2025, the Consolidation will be conducted on the basis of one (1) post-consolidation common share (“Post-Consolidation Share”) for every ten (10) pre-consolidat
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “Consolidation”) will be June 24, 2025. As outlined in the Company’s news release dated May 15, 2025, the Consolidation will be conducted on the basis of one (1) post-consolidation common share (“Post-Consolidation Share”) for every ten (10) pre-consolidation common shares (“Pre-Consolidation Share”).","length":546,"tagName":"p"},{"type":"text","content":"The Post-Consolidation Shares are scheduled to begin trading on the TSX Venture Exchange (the “TSX-V”) at the market open on June 24, 2025 under the existing symbol “RKV”. Following the Consolidation, the new CUSIP number for the common shares will be 75103L309 and the new ISIN number will be CA75103L3092. No fractional shares will be issued as a result of the Consolidation. Any fractional interest in shares resulting from the Consolidation will be rounded up to the next whole share if the fraction is one-half or greater, and down if the fraction is less than one-half. In all other respects, the Post-Consolidation Shares will have the same attributes as the Pre-Consolidation shares. Following the Consolidation, the Company will have approximately 21,148,038 common shares issued and outstanding.","length":805,"tagName":"p"},{"type":"text","content":"The exercise or conversion price and the number of common shares issuable under any of the Company’s outstanding warrants, stock options and convertible debentures, as applicable, will be proportionately adjusted to reflect the Consolidation in accordance with their respective terms.","length":284,"tagName":"p"},{"type":"text","content":"The Company’s transfer ag...